Paul Tudor Jones Athenex, Inc. Transaction History

Tudor Investment Corp Et Al

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.24 - $1.11 $54,745 - $253,196	228,105 New	228,105 $61,000
Q2 2021 Aug 16, 2021	SELL	$3.71 - $5.13 $60,127 - $83,141	-16,207 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$4.08 - $14.75 $92,481 - $334,338	-22,667 Reduced 58.31%	16,207 $70,000
Q4 2020 Feb 16, 2021	BUY	$11.06 - $14.01 $186,062 - $235,690	16,823 Added 76.29%	38,874 $430,000
Q3 2020 Nov 16, 2020	SELL	$10.26 - $14.55 $11,604 - $16,456	-1,131 Reduced 4.88%	22,051 $267,000
Q2 2020 Aug 14, 2020	BUY	$7.11 - $13.76 $164,824 - $318,984	23,182 New	23,182 $319,000

1.46M

Ticker ATNX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 156,790,000
Market Cap $1.57M
Description
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar,...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.